NASDAQ:GRI GRI Bio Q3 2025 Earnings Report $2.26 -0.02 (-0.88%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$2.28 +0.02 (+0.80%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast GRI Bio EPS ResultsActual EPS-$35.84Consensus EPS -$31.08Beat/MissMissed by -$4.76One Year Ago EPSN/AGRI Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGRI Bio Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 14, 2025Conference Call Time7:00AM ETUpcoming EarningsGRI Bio's Q2 2026 earnings is estimated for Thursday, May 21, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) GRI Bio Earnings HeadlinesGRI Bio (GRI) Expected to Announce Quarterly Earnings on ThursdayMay 14 at 2:25 AM | americanbankingnews.comGRI Bio (GRI) price target decreased by 75.16% to 163.20April 9, 2026 | msn.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 14 at 1:00 AM | Porter & Company (Ad)GRI Springs on UAE PatentApril 9, 2026 | baystreet.caGRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory ConditionsApril 8, 2026 | globenewswire.comGRI Bio, Inc. Discusses Positive Phase 2a Data in Idiopathic Pulmonary Fibrosis During Virtual Investor SegmentFebruary 17, 2026 | quiverquant.comQSee More GRI Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GRI Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRI Bio and other key companies, straight to your email. Email Address About GRI BioGRI Bio (NASDAQ:GRI), a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.View GRI Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunD-Wave Earnings Looked Weak, But Investors May Be Missing ThisPlug Power Flips The Switch On ProfitabilityHims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?On Holdings Sets Up for Marathon Rally: New Highs Are ComingShake Shack Stock Gets Shaken After Earnings Miss Upcoming Earnings Mizuho Financial Group (5/15/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
